{"id":829911,"date":"2025-03-26T08:05:47","date_gmt":"2025-03-26T12:05:47","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/trisalus-life-sciences-announces-new-cms-hcpcs-code-for-trinav-infusion-system-mapping\/"},"modified":"2025-03-26T08:05:47","modified_gmt":"2025-03-26T12:05:47","slug":"trisalus-life-sciences-announces-new-cms-hcpcs-code-for-trinav-infusion-system-mapping","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/trisalus-life-sciences-announces-new-cms-hcpcs-code-for-trinav-infusion-system-mapping\/","title":{"rendered":"TriSalus Life Sciences Announces New CMS HCPCS Code for TriNav\u00ae Infusion System Mapping"},"content":{"rendered":"<p>        <!--.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p><strong>TriSalus Life Sciences Announces New CMS HCPCS Code for TriNav\u00ae Infusion System Mapping<\/strong><\/p>\n<p>DENVER&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nTriSalus Life Sciences\u00ae, Inc. (\u201cTriSalus\u201d or the \u201cCompany\u201d) (Nasdaq: TLSI), which seeks to transform outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies and our investigational immunotherapy, announced today that the Centers for Medicare &amp; Medicaid Services (CMS) has established a new Level II HCPCS code for the TriNav\u00ae Infusion System, effective <strong>April 1, 2025<\/strong>. This new code, <strong>C8004<\/strong>, provides reimbursement clarity for simulation angiograms\u2014commonly known as mapping procedures\u2014conducted prior to transarterial radioembolization (TARE).\n<\/p>\n<p>\nThe introduction of <strong>C8004<\/strong> provides validation of <strong>TriNav\u2019s growing role in pre-treatment mapping for <\/strong><b>Transarterial Radioembolization<\/b>, reinforcing its value in optimizing Y90 dose delivery.\n<\/p>\n<p><i>\u201cWith this new code, Interventional Radiologists and Medicare patients have access to PEDD for radioembolization procedures with full reimbursement for both mapping and treatment,\u201d<\/i> said <strong>Mary Szela, CEO of TriSalus<\/strong>. <i>\u201cUsing PEDD technology for both the mapping and treatment procedures in radioembolization helps ensure accurate treatment planning and delivery which is crucial for delivering the radioactive microspheres to the tumor with precision<\/i>.\u201d\n<\/p>\n<p><b>Dr. Richard Marshall, who serves as Medical Director for TriSalus, stated:<\/b><\/p>\n<p>\n\u201c<i>In my current practice, using the same catheter for both mapping and treatment helps enhance the accuracy of Y90 dose delivery.<\/i><i>I can achieve a higher T:N ratio with the TriNav Infusion System, and I have seen that its high concordance between mapping and treatment allows better prediction of the dose which can improve personalized dosimetry.\u201d<\/i><\/p>\n<p><strong>HCPCS Code C8004 Details<\/strong><\/p>\n<ul class=\"bwlistdisc\">\n<li><strong>Description<\/strong>: Simulation angiogram utilizing a pressure-generating catheter (e.g., one-way valve, intermittently occluding), including all radiological supervision and interpretation, intraprocedural road mapping, and imaging guidance necessary for subsequent therapeutic radioembolization of tumors.\n<\/li>\n<li><strong>Effective Date<\/strong>: <strong>April 1, 2025<\/strong><\/li>\n<li><strong>Eligible Reporting Facilities<\/strong>: Hospital outpatient departments (HOPDs) and ambulatory surgical centers (ASCs)\n<\/li>\n<li><strong>Medicare Payment Rate<\/strong>: <strong>$11,341 under APC 5193<\/strong><\/li>\n<\/ul>\n<p>\nTriSalus\u2019 initial analysis indicates that the reimbursement level under <strong>C8004<\/strong>, combined with standard Medicare payment adjustments, will support continued adoption of <strong>TriNav for both mapping and treatment<\/strong>.\n<\/p>\n<p>\nFor more information, the full CMS Quarterly Update can be found <strong>[<\/strong><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cms.gov%2Fmedicare%2Fcoding-billing%2Fhealthcare-common-procedure-system%2Fquarterly-update&amp;esheet=54228864&amp;newsitemid=20250326932769&amp;lan=en-US&amp;anchor=here&amp;index=1&amp;md5=07230cd45c7a1ce157fe74e31c35ab35\">here<\/a><strong>]<\/strong>.\n<\/p>\n<p><b>About TriSalus Life Sciences<\/b><\/p>\n<p>\nTriSalus Life Sciences\u00ae is a growing, oncology focused medical technology business bringing disruptive drug delivery technology with the goal of improving therapeutic delivery to liver and pancreatic tumors. Additionally, we are exploring the integration of our technology with our investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of liver and pancreatic indications. Our ultimate goal is to transform the treatment paradigm for patients battling liver and pancreatic tumors. We have developed an innovative organ-specific platform that is designed to overcome two of the most significant challenges that prevent optimal delivery and performance of therapeutics in these difficult-to-treat diseases: (i) high intratumoral pressure caused by tumor growth and collapsed vasculature restricting the delivery of oncology therapeutics and (ii) the immunosuppressive properties of liver and pancreatic tumor immune cells. By systematically addressing these barriers, we aim to improve response to therapies and to enable improved patient outcomes.\n<\/p>\n<p>\nIn partnership with leading cancer centers across the country \u2013 and by leveraging deep immuno-oncology expertise and inventive technology development \u2013 TriSalus is committed to advancing innovation that improves outcomes for patients. Learn more at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftrisaluslifesci.com%2F&amp;esheet=54228864&amp;newsitemid=20250326932769&amp;lan=en-US&amp;anchor=trisaluslifesci.com&amp;index=2&amp;md5=6cf8b6fee5cac89aea37cf081554a0a1\">trisaluslifesci.com<\/a> and follow us on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FTriSalusLifeSci&amp;esheet=54228864&amp;newsitemid=20250326932769&amp;lan=en-US&amp;anchor=X+%28formerly+Twitter%29&amp;index=3&amp;md5=e36de7e9cb4f5e0bf61ea84fab7ea4fc\">X (formerly Twitter)<\/a> and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Ftrisaluslifesciences%2F&amp;esheet=54228864&amp;newsitemid=20250326932769&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=4&amp;md5=f8304e71cf682d53da843e4c26408621\">LinkedIn<\/a>.\n<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p><i>Certain statements made in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as \u201cbecome,\u201d \u201cmay,\u201d \u201cintend,\u201d \u201cwill,\u201d \u201cexpect,\u201d \u201canticipate,\u201d \u201cbelieve\u201d or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding TriSalus\u2019s business, the commercial potential of its TriNav Infusion System, TriSalus\u2019s proprietary PEDD approach, the potential therapeutic benefits and commercial potential of Nelitolimod, and TriSalus\u2019s technologies and other products in development. Such statements are subject to certain risks and uncertainties, including, but not limited to, those inherent in the process of developing and commercializing medical devices that are safe and effective for human use, discovering, developing and commercializing medicines that are safe and effective to use as human therapeutics, and the endeavor of building a business around such medical devices and medicines.<\/i><\/p>\n<p><i>TriSalus\u2019s forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although TriSalus\u2019s forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by TriSalus. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning TriSalus\u2019s products and programs are described in additional detail in TriSalus\u2019s annual report on Form 10-K, and most recent Form 10-Q, which are on file with the Securities and Exchange Commission (the &#8220;SEC&#8221;) and available at the SEC&#8217;s website (<\/i><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.SEC.gov&amp;esheet=54228864&amp;newsitemid=20250326932769&amp;lan=en-US&amp;anchor=www.SEC.gov&amp;index=5&amp;md5=0ef02b22576572a66c84f34b9557d220\"><i>www.SEC.gov<\/i><\/a><i>). These forward-looking statements are made as of the date of this press release, and TriSalus assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.<\/i><\/p>\n<p><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cms.gov%2Fmedicare%2Fcoding-billing%2Fhealthcare-common-procedure-system%2Fquarterly-update&amp;esheet=54228864&amp;newsitemid=20250326932769&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.cms.gov%2Fmedicare%2Fcoding-billing%2Fhealthcare-common-procedure-system%2Fquarterly-update&amp;index=6&amp;md5=149da9eab313979ddd8a7ce98afa7ac5\">https:\/\/www.cms.gov\/medicare\/coding-billing\/healthcare-common-procedure-system\/quarterly-update<\/a><\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250326932769r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20250326932769\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20250326932769\/en\/<\/a><\/span><\/p>\n<p><b>For Media Inquiries:<br \/>\n<\/b><br \/>Jeremy Feffer, Managing Director<br \/>\n<br \/>LifeSci Advisors<br \/>\n<br \/>917.749.1494<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:jfeffer@lifesciadvisors.com\">jfeffer@lifesciadvisors.com<\/a><\/p>\n<p><b>For Investor Inquiries:<br \/>\n<\/b><br \/>James Young<br \/>\n<br \/>Chief Financial Officer<br \/>\n<br \/>847.337.0655<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:james.young@trisaluslifesci.com\">james.young@trisaluslifesci.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America Colorado<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Research Medical Devices Health Technology Biotechnology Radiology Health Pharmaceutical Science Oncology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\" \/>\n","protected":false},"excerpt":{"rendered":"<p>TriSalus Life Sciences Announces New CMS HCPCS Code for TriNav\u00ae Infusion System Mapping DENVER&#8211;(BUSINESS WIRE)&#8211; TriSalus Life Sciences\u00ae, Inc. (\u201cTriSalus\u201d or the \u201cCompany\u201d) (Nasdaq: TLSI), which seeks to transform outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies and our investigational immunotherapy, announced today that the Centers for Medicare &amp; Medicaid Services (CMS) has established a new Level II HCPCS code for the TriNav\u00ae Infusion System, effective April 1, 2025. This new code, C8004, provides reimbursement clarity for simulation angiograms\u2014commonly known as mapping procedures\u2014conducted prior to transarterial radioembolization (TARE). The introduction of C8004 provides validation of TriNav\u2019s growing role in pre-treatment mapping for Transarterial Radioembolization, reinforcing its value in optimizing Y90 dose delivery. \u201cWith &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/trisalus-life-sciences-announces-new-cms-hcpcs-code-for-trinav-infusion-system-mapping\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;TriSalus Life Sciences Announces New CMS HCPCS Code for TriNav\u00ae Infusion System Mapping&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-829911","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>TriSalus Life Sciences Announces New CMS HCPCS Code for TriNav\u00ae Infusion System Mapping - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/trisalus-life-sciences-announces-new-cms-hcpcs-code-for-trinav-infusion-system-mapping\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"TriSalus Life Sciences Announces New CMS HCPCS Code for TriNav\u00ae Infusion System Mapping - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"TriSalus Life Sciences Announces New CMS HCPCS Code for TriNav\u00ae Infusion System Mapping DENVER&#8211;(BUSINESS WIRE)&#8211; TriSalus Life Sciences\u00ae, Inc. (\u201cTriSalus\u201d or the \u201cCompany\u201d) (Nasdaq: TLSI), which seeks to transform outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies and our investigational immunotherapy, announced today that the Centers for Medicare &amp; Medicaid Services (CMS) has established a new Level II HCPCS code for the TriNav\u00ae Infusion System, effective April 1, 2025. This new code, C8004, provides reimbursement clarity for simulation angiograms\u2014commonly known as mapping procedures\u2014conducted prior to transarterial radioembolization (TARE). The introduction of C8004 provides validation of TriNav\u2019s growing role in pre-treatment mapping for Transarterial Radioembolization, reinforcing its value in optimizing Y90 dose delivery. \u201cWith &hellip; Continue reading &quot;TriSalus Life Sciences Announces New CMS HCPCS Code for TriNav\u00ae Infusion System Mapping&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/trisalus-life-sciences-announces-new-cms-hcpcs-code-for-trinav-infusion-system-mapping\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-26T12:05:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250326932769r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trisalus-life-sciences-announces-new-cms-hcpcs-code-for-trinav-infusion-system-mapping\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trisalus-life-sciences-announces-new-cms-hcpcs-code-for-trinav-infusion-system-mapping\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"TriSalus Life Sciences Announces New CMS HCPCS Code for TriNav\u00ae Infusion System Mapping\",\"datePublished\":\"2025-03-26T12:05:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trisalus-life-sciences-announces-new-cms-hcpcs-code-for-trinav-infusion-system-mapping\\\/\"},\"wordCount\":981,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trisalus-life-sciences-announces-new-cms-hcpcs-code-for-trinav-infusion-system-mapping\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250326932769r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trisalus-life-sciences-announces-new-cms-hcpcs-code-for-trinav-infusion-system-mapping\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trisalus-life-sciences-announces-new-cms-hcpcs-code-for-trinav-infusion-system-mapping\\\/\",\"name\":\"TriSalus Life Sciences Announces New CMS HCPCS Code for TriNav\u00ae Infusion System Mapping - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trisalus-life-sciences-announces-new-cms-hcpcs-code-for-trinav-infusion-system-mapping\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trisalus-life-sciences-announces-new-cms-hcpcs-code-for-trinav-infusion-system-mapping\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250326932769r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2025-03-26T12:05:47+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trisalus-life-sciences-announces-new-cms-hcpcs-code-for-trinav-infusion-system-mapping\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trisalus-life-sciences-announces-new-cms-hcpcs-code-for-trinav-infusion-system-mapping\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trisalus-life-sciences-announces-new-cms-hcpcs-code-for-trinav-infusion-system-mapping\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250326932769r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250326932769r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trisalus-life-sciences-announces-new-cms-hcpcs-code-for-trinav-infusion-system-mapping\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"TriSalus Life Sciences Announces New CMS HCPCS Code for TriNav\u00ae Infusion System Mapping\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"TriSalus Life Sciences Announces New CMS HCPCS Code for TriNav\u00ae Infusion System Mapping - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/trisalus-life-sciences-announces-new-cms-hcpcs-code-for-trinav-infusion-system-mapping\/","og_locale":"en_US","og_type":"article","og_title":"TriSalus Life Sciences Announces New CMS HCPCS Code for TriNav\u00ae Infusion System Mapping - Market Newsdesk","og_description":"TriSalus Life Sciences Announces New CMS HCPCS Code for TriNav\u00ae Infusion System Mapping DENVER&#8211;(BUSINESS WIRE)&#8211; TriSalus Life Sciences\u00ae, Inc. (\u201cTriSalus\u201d or the \u201cCompany\u201d) (Nasdaq: TLSI), which seeks to transform outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies and our investigational immunotherapy, announced today that the Centers for Medicare &amp; Medicaid Services (CMS) has established a new Level II HCPCS code for the TriNav\u00ae Infusion System, effective April 1, 2025. This new code, C8004, provides reimbursement clarity for simulation angiograms\u2014commonly known as mapping procedures\u2014conducted prior to transarterial radioembolization (TARE). The introduction of C8004 provides validation of TriNav\u2019s growing role in pre-treatment mapping for Transarterial Radioembolization, reinforcing its value in optimizing Y90 dose delivery. \u201cWith &hellip; Continue reading \"TriSalus Life Sciences Announces New CMS HCPCS Code for TriNav\u00ae Infusion System Mapping\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/trisalus-life-sciences-announces-new-cms-hcpcs-code-for-trinav-infusion-system-mapping\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-26T12:05:47+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250326932769r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trisalus-life-sciences-announces-new-cms-hcpcs-code-for-trinav-infusion-system-mapping\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trisalus-life-sciences-announces-new-cms-hcpcs-code-for-trinav-infusion-system-mapping\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"TriSalus Life Sciences Announces New CMS HCPCS Code for TriNav\u00ae Infusion System Mapping","datePublished":"2025-03-26T12:05:47+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trisalus-life-sciences-announces-new-cms-hcpcs-code-for-trinav-infusion-system-mapping\/"},"wordCount":981,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trisalus-life-sciences-announces-new-cms-hcpcs-code-for-trinav-infusion-system-mapping\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250326932769r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trisalus-life-sciences-announces-new-cms-hcpcs-code-for-trinav-infusion-system-mapping\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/trisalus-life-sciences-announces-new-cms-hcpcs-code-for-trinav-infusion-system-mapping\/","name":"TriSalus Life Sciences Announces New CMS HCPCS Code for TriNav\u00ae Infusion System Mapping - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trisalus-life-sciences-announces-new-cms-hcpcs-code-for-trinav-infusion-system-mapping\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trisalus-life-sciences-announces-new-cms-hcpcs-code-for-trinav-infusion-system-mapping\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250326932769r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2025-03-26T12:05:47+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trisalus-life-sciences-announces-new-cms-hcpcs-code-for-trinav-infusion-system-mapping\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/trisalus-life-sciences-announces-new-cms-hcpcs-code-for-trinav-infusion-system-mapping\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trisalus-life-sciences-announces-new-cms-hcpcs-code-for-trinav-infusion-system-mapping\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250326932769r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250326932769r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trisalus-life-sciences-announces-new-cms-hcpcs-code-for-trinav-infusion-system-mapping\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"TriSalus Life Sciences Announces New CMS HCPCS Code for TriNav\u00ae Infusion System Mapping"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/829911","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=829911"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/829911\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=829911"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=829911"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=829911"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}